Antimicrobial treatment for intra-abdominal infections

Area of Science:

• Infectious Diseases
• Clinical Microbiology
• Surgical Infections

Background:

• Complicated intra-abdominal infections (cIAI) necessitate antimicrobial therapy alongside source control.
• Antimicrobial regimens targeting gram-negative and anaerobic enteric pathogens are standard treatment.
• Treatment strategies differ based on infection acquisition: community-acquired versus nosocomial.

Purpose of the Study:

• To outline appropriate antimicrobial therapy for complicated intra-abdominal infections.
• To differentiate treatment approaches for community-acquired versus nosocomial infections.
• To emphasize the importance of pathogen resistance and de-escalation strategies.

Main Methods:

• Review of current antimicrobial treatment guidelines for intra-abdominal infections.
• Analysis of pathogen prevalence and resistance patterns in community-acquired versus nosocomial cIAI.
• Discussion of empiric therapy, spectrum of activity, and de-escalation principles.

Main Results:

• For community-acquired cIAI, comparable efficacy exists among various recommended antimicrobial regimens; narrower spectrum agents are suitable.
• Nosocomial cIAI often involve resistant pathogens, necessitating broader-spectrum empiric antimicrobial therapy.
• Consideration of agents covering resistant gram-negatives, anaerobes, enterococci, resistant staphylococci, and Candida is advised for nosocomial infections.

Conclusions:

• Antimicrobial selection for cIAI should be guided by the infection source and local resistance patterns.
• Empiric therapy for nosocomial cIAI requires broader coverage, with de-escalation post-culture results.
• Appropriate antimicrobial stewardship is key to optimizing treatment and preventing resistance.